Navigation Links
GeoVax Labs, Inc. Information To Be Available Through Standard & Poor's Market Access Program
Date:10/1/2008

ATLANTA, Oct. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of GeoVax Labs, Inc. will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be eff
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
6. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
7. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
8. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
9. IFRS Information - First Half of 2007
10. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
11. Researchers improve ability to write and store information on electronic devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Oven Industries Inc. ... ramp/soak capabilities. The 5R6-900 benchtop controller has many outstanding ... can be plugged into the wall as a self-contained ... This distinctive detail makes the device unique, as well ... laboratory temperature controller can also be used universally, which ...
(Date:5/20/2013)... May 20, 2013 Today, at the American ... , James McGough , M.D., ... the Semel Institute for Neuroscience and Human Behavior and ... at the University of California Los Angeles (UCLA), and ... Adolescent Psychopharmacology and ADHD at UCLA, presented the results ...
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... With bed bugs' presence come problems in ... bugs need to be eliminated, one must make sure that ... health. And so to help bed bug sufferers get that ... of bed bugs without using harmful pesticides. In it, ... called Bed Bug Bully. , According to My Cleaning Products, ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2
... strain of virus broadens government readiness program -, ... the vaccines division of sanofi-aventis Group, announced,today that the ... H5N1 bulk vaccine antigen to produce approximately 38.5 million,doses ... avian influenza. Sanofi,Pasteur has a multi- year contract with ...
... CHINA, April 28 Simcere,Pharmaceutical Group (NYSE: ... generic pharmaceuticals and manufacturer of the patented,anti-cancer biotech ... has been,informed that one of its existing shareholders, ... beneficially owned by 15,individuals, including certain senior management ...
... 28 MBF Healthcare,Acquisition Corp. (Amex: MBH ... today that it and Critical Homecare,Solutions Holdings, Inc. ... therapy and specialty infusion services, are,scheduled to present ... Annual Deutsche,Bank Healthcare Conference in Boston, MA. On ...
Cached Biology Technology:U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 2U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 3U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 4Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 3
(Date:5/19/2013)... Researchers have engineered a strain of electricity-producing bacteria that ... donor and carbon dioxide as its sole source of ... report their findings at the 113th General Meeting of ... first result of current production solely on hydrogen," says ... with his co-authors are part of the Lovley Lab ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... Bethesda, MD (May 18, 2013) The AGA Research ... research into the relationship between the gut microbiota, one ... health and disease. , The AGA Research Awards ... colleagues from Massachusetts General Hospital and Harvard Medical School, ... Award recipient. Dr. Chan will receive $25,000 of funding, ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... Reportlinker.com announces that a new market research report is ... Markets: Microarrays and Lab-on-a-Chip http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html ... STUDY GOALS AND OBJECTIVES BCC,s ... of current and emerging biochip technologies and products, and ...
... of Escherichia coli causing a severe illness called hemolytic-uremic syndrome ... killed more than 20 people and sickened more than 2,000. ... strain of E. coli O104:H4 that produces a ... E. coli O157:H7. Two isolates from this outbreak ...
... Ore. June 6, 2011. Sustainability is the theme for ... Society, scheduled to meet in Portland June 19 to ... others from academia, government, non-profit groups, and private industry ... products industry and share information about innovations in the ...
Cached Biology News:Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15Two isolates from E. coli outbreak available 2
PFM8 Antibody...
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Component in MasterPure™ Purification Kits...
Biology Products: